New drug added to transplant could stop blood Cancer's return
NCT ID NCT07183878
Summary
This study is testing if adding a drug called venetoclax to the standard pre-transplant chemotherapy improves outcomes for people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). About 138 patients aged 12-60 will be randomly assigned to receive either the standard transplant regimen or the new regimen with venetoclax. The main goal is to see if the new approach helps patients live longer without their cancer coming back after the transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.